

1 Proteogenomic analysis identifies the persistence of targetable lesions and proteomes through
2 disease evolution in pediatric acute lymphoblastic leukemia

3
4 Amanda C. Lorentzian^{1,2}, Meiyun Guo^{1,2}, Enes K. Ergin^{2,3}, Neha M. Akella^{1,2}, Nina Rolf^{1,2}, C.
5 James Lim^{1,2}, Gregor S.D. Reid^{1,2}, Christopher A. Maxwell^{1,2,4}, Philipp F. Lange^{2,3,4}

6
7 Affiliations:

8 ¹Department of Pediatrics, University of British Columbia, Vancouver, CANADA

9 ²Michael Cuccione Childhood Cancer Research Program at the BC Children's Hospital Research
10 Institute, Vancouver, CANADA

11 ³Department of Pathology, University of British Columbia, Vancouver, CANADA

12
13
14 ⁴Correspondence to: Christopher A. Maxwell PhD

15 BC Children's Hospital

16 950 West 28th Avenue

17 Vancouver, BC

18 Canada V5Z 4H4

19 cmaxwell@bcchr.ca

20
21 Philipp F. Lange PhD

22 BC Children's Hospital

23 950 West 28th Avenue

24 Vancouver, BC

25 Canada V5Z 4H4

26 philipp.lange@ubc.ca

27

28

29 The authors declare no potential conflicts of interest

30 **ABSTRACT**

31 Childhood acute lymphoblastic leukemia (ALL) genome landscapes indicate that relapses often
32 arise from subclonal outgrowths. However, the impact of clonal evolution on the actionable
33 proteome and response to targeted therapy is not known. Here, we present a comprehensive
34 retrospective analysis of paired ALL diagnosis and relapsed specimen. Targeted next generation
35 sequencing and proteome analysis indicated persistence of genome variants and stable proteomes
36 through disease progression. Although variant-targeted therapies showed poor selectivity against
37 viably-frozen tumor samples, paired samples showed high correlation of drug response.
38 Proteome analysis prioritized PARP1 as a new pan-ALL target candidate; diagnostic and
39 relapsed ALL samples demonstrated robust sensitivity to treatment with two PARP1/2 inhibitors.
40 Together, these findings support initiating prospective precision oncology approaches at ALL
41 diagnosis and emphasize the need to incorporate proteome analysis to prospectively determine
42 tumor sensitivities, which are likely to be retained at disease relapse.

43
44 **STATEMENT OF SIGNIFICANCE:** We discover that disease progression and evolution in
45 pediatric acute lymphoblastic leukemia is defined by the persistence of targetable genomic
46 variants and stable proteomes, which reveal pan-ALL target candidates. Thus, personalized
47 treatment options in childhood ALL may be improved with the incorporation of prospective
48 proteogenomic approaches initiated at disease diagnosis.

50 **INTRODUCTION**

51 Relapsed cancer is a leading disease-related cause of death for children and adolescents (1).
52 Targeting the specific molecular changes that arise in cancer cells may improve patient survival
53 (2); for this reason, clinical trials centred on next generation sequencing (NGS)-based
54 identification of biomarkers and targetable pathways are currently establishing patient enrolment
55 strategies, clinical protocols, and critical safety data for personalized therapies. Most trials are
56 currently limited to high-risk or recurrent disease. However, fast progressing disease often limits
57 successful treatment options. In certain cases, precision oncology trials may be initiated at
58 diagnosis. However, a major challenge for prospective precision oncology approaches is our
59 limited understanding of lesion persistence or evolution, as tumour variants can be gained or lost
60 at relapse.

61
62 There is now a wealth of publicly available data for genomic characterization of paired diagnosis
63 and relapse specimens from children with cancer. Clonal evolution does occur in pediatric
64 leukemia wherein a minor clone, present only at low frequencies at diagnosis, is selected at time
65 of relapse (3,4). While these studies show evolution in single nucleotide variants, often through
66 chemotherapy-induced mutation (5), structural variants change less frequently with leukemia
67 progression.

68
69 Few studies have yet investigated how protein levels change from diagnosis to relapse, especially
70 pertaining to therapeutic targets. A previous proteomic analysis of matched diagnostic and
71 relapsed B-cell precursor acute lymphoblastic leukemia (ALL) specimens, sourced from
72 pediatric and adult patients, observed increased protein levels in specific pathways at relapse,
73 including glycolysis, phosphate pentose pathway and metabolic pathways that may contribute
74 to chemo-resistance (6). Since proteins are the actual therapeutic targets (7,8), it is crucial to
75 better understand the pediatric tumor proteome to determine how the response to therapy may
76 change through progression. Here, we present a comprehensive interrogation of ALL
77 proteogenome dynamics from diagnosis to relapse in paired patient specimens, specifically to
78 understand how cancer-driving and potentially targetable lesions persist or differentiate through
79 disease progression.

80 81 **RESULTS**

82 **NGS reveals stability of affected genes through ALL disease progression**

83 To examine proteogenomic evolution in pediatric ALL, we sourced paired initial diagnosis (Dx)
84 and relapse (R) bone marrow mononuclear cells from patients (n=11) or non-cancer pediatric
85 participants (n=3) seen at BC Children's Hospital (BCCH) (Supplementary Table S1). We first
86 explored the mutational landscape via targeted, pediatric cancer-focused NGS analysis in paired
87 progression samples (n=10 B-ALL, n=1 T-ALL) (9). Across the BCCH cohort, we detected
88 recurrent copy number variants (CNV) or single nucleotide variants (SNV) in *CDKN2A/B*,
89 *NRAS*, *KRAS*, *IKZF*, *JAK1*, and *JAK2* (Fig. 1A, Supplementary Fig. S1 and Supplementary Table
90 S2), which are commonly mutated in pediatric ALL samples (8). Nine of the eleven patients had
91 at least 50% retention of mutations and four of these patients had 100% retention of mutations.

Figure 1: NGS reveals stability of affected genes through ALL disease progression




Figure 1: NGS reveals stability of affected genes through ALL disease progression

A. Mutated gene products identified through targeted DNA/RNA-fusion sequencing of paired diagnosis (Dx) and relapse (R) samples. Mutations detected in both Dx and R samples are represented by green boxes, mutations unique to Dx are dark purple, and R unique are light purple. CNVs are full boxes and SNVs are outlined boxes. The pie diagrams at the top summarize the number of mutations for each category for each patient. An asterisk indicates multi timepoint patients; BALL01 R2-R3-R4-R5-R5P, BALL02 Dx-R1-R2.

B. Circos plot for all mutations identified in the BCCH cohort demonstrating mutations that were Dx unique, R unique, or shared between Dx and R samples.

C. Circos plot for all mutations identified in the SJH cohort demonstrating mutations that were Dx unique, R unique, or shared between Dx and R samples.

D. Fraction of variants identified as D unique, R1 unique, or shared within paired samples sourced from 80 ALL patients (n= 11 from BCCH represented by squares, n= 69 from SJH represented by circles). The black bar represents the median of the population.

E. Dot plot for fraction of shared variants versus time to relapse for 80 ALL patients (n= 11 from BCCH represented by squares, n= 69 from SJH represented by circles).

F. Dot plot for fraction of shared variants separated by disease subtype for 80 ALL patients (n= 11 from BCCH represented by squares, n= 69 from SJH represented by circles). The black bar represents the median of the population.

92 The majority was retained from Dx to R: nine of the eleven patients had at least 50% retention of
93 mutations and four of these patients had 100% retention of mutations, indicating high stability of
94 lesions in this cohort.

95
96 At time of relapse of pediatric ALL, clonal evolution frequently includes the outgrowth of clones
97 defined by a different mutational site within the same affected gene; for example, a relapse clone
98 with KRAS.A146T replaces the diagnostic KRAS.G12D clone (3). Since alternate pathogenic
99 mutations in the same gene often serve as biomarkers for the same targeted treatment, we
100 focused our analysis on the affected gene, rather than the mutation site. We evaluated the
101 detected lesions grouped by detection only at diagnosis (Dx unique), only at relapse (R unique),
102 or at both timepoints (shared). Here we found 67% (30 of 45) of affected genes were shared
103 between paired diagnosis and relapse samples in the BCCH cohort (Fig. 1B). To determine the
104 generalizability of this finding, we mined public NGS datasets from ALL cases (n=49 B-ALL;
105 n=20 T-ALL) treated at St. Jude's Hospital (SJH) (Supplementary Table S3) (10). Consistently,
106 genes found to be mutated at diagnosis were most often also mutated at relapse in B-ALL and T-
107 ALL patients, including several known pediatric cancer-driving genes (Fig. 1C and
108 Supplementary Fig. S2). Samples collected from BCCH and SJH showed similar distributions of
109 affected genes that were shared between time-points or were unique to Dx or R (Fig. 1C,D and
110 Supplementary Table S4), with the majority of variants shared between paired diagnosis and
111 relapse samples (Fig. 1C). In fact, the genes that were persistently mutated through disease
112 progression were highly similar in both cohorts, including *CDKN2A/B*, *IKZF1*, and *N/KRAS*,
113 with structural variants being retained with higher frequency than SNVs (Supplementary Fig.
114 S3A-C). Surprisingly, retention of genetic lesions was not correlated with the time between
115 diagnosis and first relapse, or between relapses. (Fig. 1E and Supplementary Fig. S3D,E).
116 However, we observed relatively higher stability for Hyperdiploid (hyper), Philadelphia + (PH),
117 and early T-cell precursor (ETP) sub-types (Fig. 1E).

118 119 **Matched patient-derived leukemic cells respond similarly to variant-selected agents**

120 Persistence of affected genes suggests that sensitivity to precision therapies may also persist with
121 disease progression. To examine this, we paired affected genes with targeted agents following
122 the Pediatric MATCH strategy and evidence from clinical trials or case reports, as described (9).

123 In the SJH and BCCH cohorts (n=80 paired samples), we found 64% of ALL patients (51 of 80)
124 retained at least one variant-agent pairing at disease relapse; in fact, nearly 50% of patients (38
125 of 80) showed complete retention of variant-agent pairings through disease progression (Fig. 2A
126 and Supplementary Table S5). Only six patients had variant-agent pairings unique to the
127 diagnostic timepoint, while 10 patients harbored no targetable mutations (Fig. 2A).

128
129 We sourced viably-frozen paired bone marrow mononuclear cells (BM-MNC) from six patients
130 treated at BCCH, including four paired BM-MNC that showed retention of all affected genes and
131 two paired specimens with partial/no retention (Fig. 2B). Within this cohort, we identified four
132 variant-agent pairings and then treated viable patient specimen with graded doses of a
133 representative targeted agent (CDK4/6: palbociclib; MEK: Trametinib, JAK/STAT: Ruxolitinib;
134 SMO: Vismodegib). We used image-based drug screening of B-ALL cells co-cultured with
135 mesenchymal stromal cells (MSC) to determine IC50 values for each sample after exposure (for
136 48-72 hours) to the four different targeted agents (Fig. 2B). Overall, the measured IC50 values
137 revealed poor selectivity, with predicted responses to trametinib being an exception. Trametinib
138 IC50 values were lower for patient samples predicted to be sensitive to MEK inhibition (Fig.
139 2C). In contrast, Palbociclib IC50 values did not differ within the primary ALL cohort (Fig. 2C)
140 suggesting cytotoxicity is induced in a non-targeted manner by this agent. Overall, the measured
141 IC50 values in relapsed samples correlated with values measured in matched diagnostic samples
142 (Pearson's $r = 0.85$, $p = 6.0e-7$, Fig. 2D). Therefore, our analysis reveals stability of actionable
143 gene lesions as well as highly correlated, though poorly selective, drug sensitivities for matched
144 pediatric ALL disease progression samples.

145
146 **Proteome investigation of matched specimens reveals stable levels of cancer-associated**
147 **proteins and processes.**

148 Ultimately, drug sensitivity is determined by the state of the targeted and compensatory protein
149 pathways. To determine whether the observed persistence of cancer-associated targetable
150 genomic lesions and associated drug sensitivities can be generalized, we next questioned if the
151 protein levels of pediatric cancer-associated proteins (CAPs) (Supplemental Table S6) follow the
152 same trend. We employed a data independent acquisition approach (DIA) using a spectral library
153 of 8183 proteins to examine six primary matched Dx-R or R-R sets (BALL01, BALL03,

Figure 2: Matched patient-derived leukemic cells respond similarly to variant-selected agents




Figure 2: Matched patient-derived leukemic cells respond similarly to variant-selected agents

A. Predicted sensitivity to targeted agents in paired Dx-R samples (or Dx-R2, R2-R3 indicated by an asterisk) taken from 80 ALL patients treated at BCCH (n=11, light blue) or SJH (n=69, dark blue). B-ALL (light brown) and T-ALL (dark brown) samples are indicated. Shared variants (green), Dx unique variants (dark purple), or R unique variants (light purple) are indicated. Agent-variant pairs were assigned following the strategy outlined in the Pediatric Match Trial (9).

B. Measured IC50 values for viably frozen ALL samples from patients treated at BCCH (n= 6 patients) and representative cell lines. ALL samples were co-cultured with hTERT-MSCs and separately treated with four inhibitors, MEKi, CDK4/6i, JAK/STATi, and SMOi. IC50 [uM] are colored by most sensitive in yellow to least sensitive in blue. Measurements represent the mean of n=2 replica wells from a single experiment.

C. Dot plots for IC50 [uM] values measured for primary samples or cell lines for each drug. Samples are separated based on the presence (pink) or absence (black) of a genomic variant predicted to augment drug sensitivity.

D. Correlation of IC50 [M] values measured for paired Dx and R paired samples. Individual drugs are indicated by unique identifiers. r= Pearson correlation coefficient.

154 BALL04, BALL05, BALL06, BALL07, one PDX-derived Dx-R-R set (BALL02), and three
155 non-cancer bone marrow (BM) specimens (Supplementary Fig. S4, S5 and Supplementary
156 Tables S7, S8). Across cases, we identified 45 CAPs to be significantly more abundant in
157 diagnosis specimens (n = 6) or relapse specimens (n = 12) compared to non-cancer controls (n =
158 3) (Supplementary Fig. S6A-D and Supplementary Table S9). Of these 45 proteins, we identified
159 several proteins that are commonly overexpressed in acute lymphoblastic leukemias such as
160 FLT3, CDK6, and EBF1 (11). The majority (n = 36 proteins) showed increased abundance at
161 both disease time-points (Fig. 3A) and their abundance levels were positively correlated between
162 diagnosis and relapse (or relapse-relapse) (Pearson's $r = 0.75$, $p < 2.2e-16$); similarly, proteins
163 with lower abundance (n = 10 proteins in either disease state) showed significant positive
164 correlation between disease states (Pearson's $r = 0.70$, $p < 3.5e-15$) (Supplementary Fig. S6E-F).
165 Restricting the comparisons to matched specimens (n = 7 patients) confirmed that the high
166 correlation was retained at the level of individual patients (Fig. 3B, Pearson's $r = 0.67 - 0.90$.
167 These initial findings showed stable levels of pediatric CAPs through disease progression.

168
169 After observing high stability of protein abundance in the subset of CAPs, we investigated the
170 full proteome to better understand inter- and intra- patient stability among the disease states. We
171 tested all possible patient and timepoint pairings for statistically significant equivalence. As
172 expected, significant equivalence of protein abundance was lowest when proteomes of non-
173 cancer specimens were compared to proteomes of cancer specimens (63% or 68% equivalent to
174 Dx or R, respectively) (Fig. 3C and Supplementary Fig. S7A). In contrast, >90% of robustly
175 quantified proteins showed equivalent abundance when comparing proteomes of diagnosis and
176 relapse specimens, or multiple relapses, from the same patient (Fig. 3C, Supplementary Fig. S7B
177 and Supplementary Table S10). Consistent with our analysis of genomic stability and CAP
178 correlation, only BALL05 and BALL06 showed lower equivalence (59% and 69% respectively)
179 (Fig. 3C). At only 75% (median equivalence), different patients at either diagnosis or relapse
180 show significantly lower proteome equivalence than individual patients through progression
181 (Fig. 3C).

182
183 To determine processes that are particularly stable throughout progression, we next performed a
184 gene set and pathway enrichment analysis. Proteins found to be equivalent between cancer and

Figure 3: Proteome investigation of matched specimens reveals stable levels of cancer associated proteins and processes are stable




Figure 3: Proteome investigation of matched specimens reveals stable levels of cancer-associated proteins and processes.

- A.** From the list of 269 pediatric cancer associated proteins (CAPs), 141 proteins were detected in our data and 45 proteins were deemed significant (LIMMA analysis of Initial Diagnosis (Dx) samples vs. non-cancer bone marrow (BM) samples and Relapse (R) vs non-cancer BM samples ($\log_2FC > 1$, p-value adjusted BH-FDR < 0.05). Circos plot summarizes significantly overexpressed cancer associated proteins (CAPs).
- B.** Of the 45 proteins that were overexpressed, the protein expression for each protein that was overexpressed at Dx, was plotted as timepoint 1 (T1) vs timepoint 2 (T2), where T1 is the earliest timepoint available for the specimen (calculated as the $\log_2(\text{protein expression}/\text{the average protein expression in the non-cancer BM})$). Pearson's r correlation was calculated for all sample pairs. In cases that we had multiple time-points (BALL01 and BALL02) the correlation was calculated for consecutive pairings and are represented by the different colored dots.
- C.** Summary of tests for equivalence (Two-one-sided t-test (TOST) for equivalence, boundaries between $\log_2FC < -1$ and $\log_2FC > 1$) of protein abundance between different groups and pairings. Only statistically measurable proteins are represented. Each dot represents the mean equivalence or difference of all protein abundance for a pairing. Significance is assigned by mann-whitney wilcoxon test, *** indicates p-value $\leq .0001$.
- D.** Pathway enrichment analysis of the stable population of proteins represented in green and relapse enriched population of proteins represented in purple. The color of the circles indicates the enrichment FDR and size represents the number of identifications for the term.
- E.** Abundance of transcription factors of interest for each sample separated by timepoint (T1 or T2, black) compared to protein expression in mature B-cells (n=2 samples) isolated from peripheral blood mononuclear cells (grey).
- F.** Dot plots represent the \log_2FC of timepoint 1(T1)/timepoint 2(T2) for each of the proteins for each sample. The shaded green area indicates the stable range of -1 to 1FC. *For patients with multiple timepoints (BALL01 and BALL02) only the \log_2 ratio of the earliest timepoint/the latest timepoint is represented for simplicity.
- G.** Enriched transcription factor (TF) motifs by FDR-adjusted \log_{10} p-value. Light blue text indicates TFs that are regulated by CDK4/6 and MEK pathway. Simplified diagrams of these pathways are demonstrated below

185 non-cancer were removed prior to the enrichment analysis to eliminate ‘housekeeping’
186 mechanisms. Pathway enrichment analysis identified processes linked to overall cell survival as
187 equivalent amongst cancer proteomes, including transcription related processes, metabolic
188 processes, and cellular responses to DNA (Fig. 3D and Supplementary Table S11). Within the
189 small set of proteins that differed between diagnosis and relapse, no enriched terms specific to
190 the diagnostic timepoint could be identified. At relapse, processes involving cell adhesion,
191 indicating more motility and proliferative mechanisms, and immune response (leukocyte
192 activation, neutrophil activation involved in immune response, granulocyte activation, and
193 exocytosis, among others) were found enriched (Fig. 3D and Supplementary Table S12). We
194 next probed proteins involved in B-cell development, IKZF1, EBF1, PAX5, VPREB1, and TCF
195 (12), that are commonly dysregulated in ALL. Overall abundance of these proteins was
196 significantly higher in cancer samples than in mature B-cells isolated from non-cancer peripheral
197 blood mononuclear cells (PBMCs) (Fig. 3E and Supplementary Table S13). Moreover, for most
198 patients, stable abundance was observed between disease states (Fig. 3E, F).

199
200 Finally, we examined transcription factor (TF) motifs associated with the regulation of genes
201 encoding for equivalent proteins and identified enrichment of motifs relating to the E2Fs, ELK-1
202 and MYC transcription factors (Fig. 3G and Supplementary Table S14). Importantly, these TFs
203 are primarily activated by the CDK4/6 and MEK pathways (Fig. 3G). Consistently, genomic
204 deletion of CDKN2A (11 of 14 samples) and RAS activating mutations (8 of 14 samples) were
205 recurrent in the BCCH cohort, as previously described in Fig. 1A. Overall, pathway enrichment
206 analysis characterized proliferative and transcriptionally active pathways to be stable during
207 disease progression. Furthermore, we observed stable expression of keystone proteins and the
208 enrichment of transcription factors that are directly influenced by stable and recurrent genetic
209 lesions.

210

211 **Whole proteome discovery-driven analysis identifies pan-ALL protein targets**

212 The measured cytotoxicity was disappointing for agents informed by the Pediatric Match genetic
213 variant-agent prioritization strategy (Fig. 2C) leading us to probe our proteome datasets for new
214 targets. To discover pan-ALL protein targets, we first filtered for proteins identified in more than
215 40% of specimens and with a high overall abundance (log₁₀ intensity) and strong abundance

216 increase over non-cancer (log₂ FC) (cut-off: at least 95th percentile for both metrics) (Fig. 4A).
217 We defined stable protein abundance between paired diagnostic and relapsed samples as a model
218 variable for target discovery; using this criterium, and representing patient BALL01 as an
219 example (Fig. 4B), we generated a ranked list of new pan-ALL targets, which included HSPB1,
220 PARP1, and PRDX1 as top-ranked candidates (Fig. 4C). We selected to further characterize
221 PARP1 as a candidate target since PARP1/2 inhibitors are already developmental therapeutics
222 for a variety of pediatric tumors (13). Additionally, PARP1 is activated by DNA damage as a
223 repair mechanism (14), and “cellular responses to DNA damage”, showed enrichment in our
224 prior pathway enrichment analysis, providing further confirmation that this pathway is
225 overexpressed and stable (Fig. 3E). We sourced viably-frozen ALL samples (n=13) from the
226 BCCH Biobank, including matched specimens used in our discovery cohort (n= 4), additional
227 ALL specimens (n=13), and non-cancer pediatric stem cell samples (n=5), and treated these
228 samples with graded doses of two PARP1/2 inhibitors, Olaparib and PJ34. Image-based drug
229 screening of ALL cells co-cultured with MSC demonstrated high cytotoxic specificity of
230 PARP1/2 inhibitors for ALL relative to non-cancer stem cell samples, as determined by IC₅₀
231 values for each sample (Fig. 4D,E). The significant sensitivity of ALL cells to PARP1/2
232 inhibitors relative to non-cancer cells indicates that this may be a potential pan-ALL therapeutic
233 target that was initially discovered through protein abundance analysis.

234

235 **DISCUSSION**

236 Molecularly guided targeted therapies have a high potential to improve outcomes for pediatric
237 cancer patients. Yet, only 3-58% of patients receive molecularly guided therapies and even fewer
238 report a positive response to treatment in NGS-guided trials (15). These unsatisfactory outcomes
239 are likely the result of multiple limitations, including the reliance on genomics for target
240 identification, which cannot capture plasticity of downstream transcriptional, translational and
241 post-translational processes that impact target abundance and drug sensitivity, and the restricted
242 enrollment for high-risk or relapsed cancers, which often progress quickly. Several initiatives,
243 including ZERO and INFORM, have recently exemplified the use of precision oncology at
244 diagnosis to help refine, or even change subtype diagnosis for several cancer types, which can
245 lead to more appropriate treatment options (16,17). It is actively debated whether initiating
246 molecular analyses for precision oncology at diagnosis is beneficial. Here, we advance the

A

Figure 4: Whole proteome discovery-driven analysis identifies pan-ALL protein targets




Figure 4: Whole proteome discovery-driven analysis identifies pan-ALL protein targets

A. Correlation of log₂ fold-change (FC)/non-cancer vs protein expression (log₁₀ intensity) for all proteins in all samples (filtered for proteins identified in at least ten of seventeen samples). Dashed lines represent cut-offs for top five percent of the population for each parameter. Proteins that meet both cut-offs are colored in orange and PARP expression is represented by blue triangles.

B. Representative figure (BALL01) showing all proteins that are >log₂FC of 1.7. Only the proteins that have log₁₀ intensity >6.0 (top 5%) are colored in orange.

C. Summary of all proteins of interest (proteins that pass all cut-offs) plotted by number of samples the protein meets the indicated parameters.

D. Measured IC₅₀ values for Olaparib or PJ34 measured against ALL or non-cancer samples from patients treated at BCCH (n= 5 non-cancer, 8 diagnostic samples, 10 relapse samples). Samples were co-cultured with hTERT-MSCs and separately treated with the two PARP1/2 inhibitors. IC₅₀ [μM] are colored by most sensitive in yellow to least sensitive in blue. Measurements represent the mean of n=2 replica wells from a single experiment. Bolded Patient IDs indicate patient samples analyzed in the pan-ALL target proteomic analysis.

E. Dot plots for IC₅₀ [μM] values for Olaparib or PJ34 measured against non-cancer specimens (black square), primary diagnostic samples (light brown circle) or primary relapse samples (black circle). Measurements represent the mean of n=2 replica wells from a single experiment. Significance (*, **) is assigned by t-test p-value <0.01 and p-value <0.001 respectively.

247 debate by contributing new evidence of high retention of druggable targets in pediatric ALL. We
248 show that the stability extends to and may even be more pronounced at the protein level and that
249 proteome analysis can inform target selection in addition to and independent of genomic
250 analysis.

251
252 One challenge to initiating precision medicine at diagnosis is the prospect that the dominant
253 relapse clones contain distinct mutations and unique drug sensitivities (3,18–20). While it is
254 estimated that 37% of primary tumours retain druggable events at relapse (15), we show that a
255 far higher fraction (64% of 80 patients) of primary ALL retain at least one druggable target. This
256 high level of persistence was further reflected in the overall correlation of drug sensitivities
257 between diagnosis and relapse. In our assay, genome variants predicted sensitivity to a targeted
258 MEK inhibitor, which is consistent with prior studies (21,22). However, we found no correlation
259 between the presence of *CDKN2A* deletion in primary ALL samples and sensitivity to CDK4/6
260 inhibition. Indeed, the utility of *CDKN2A* deletion to act as a predictive biomarker for sensitivity
261 to CDK4/6 inhibitors is currently unresolved (23–26). Taken together, our data supports the
262 notion that common genomic biomarkers are not sufficient to predict tumor sensitivity to variant-
263 targeted monotherapies (27).

264
265 To supplement NGS-guided target identification, some precision oncology initiatives are
266 complementing genome analysis with additional molecular strategies such as RNA-seq or
267 Methyl-seq (15,16,28). Our study is among the first to conduct comprehensive targeted and non-
268 targeted, paired Dx and Relapse proteome analyses of pediatric ALL. We found that tumour
269 proteomes provide novel insights into disease biology and progression. For instance, targeted
270 sequence analysis indicated considerable evolution in BALL03, but the CAP proteome analysis
271 was highly stable ($r=0.78$ $p<4.1e-07$). Similarly, the relapse BALL04 sample gained a TP53
272 mutation, but CAP stability, proteome stability (equivalence of 90%), and drug responses were
273 highly correlated with the diagnostic sample. Thus, evolution of minor clones through disease
274 progression may not dramatically impact the expressed proteomes.

275
276 Proteomic analysis can also reveal new potential targets (29–31). Consistently, we identified
277 PARP1, PRDX1 and HSPB1 as overexpressed pan-ALL target candidates. Moreover, we

278 validated the sensitivity of B-ALL samples to PARP1/2 inhibition *in vitro*. These proteome-
279 based pan-ALL targets may warrant further investigation of their actionability in pediatric ALL.
280 However, we note the conclusions drawn from our proteome analyses and image-based drug
281 screening are limited by the number of matched patient samples examined, the variety of genetic
282 subtypes, and the ethnic diversity of the patients treated in our single site cohort. In addition,
283 image-based drug screening of ex vivo ALL-MSC co-cultures may not accurately reflect
284 responses in patients although it has been shown to capture leukemia-intrinsic differences in cell
285 proliferation and survival and, in the case of venetoclax, ex vivo responses correlate with strong
286 *in vivo* antileukemic activity (32). Finally, our retrospective design was useful for studying
287 matched Dx-R samples, which are relatively rare and difficult to predict prospectively. With
288 these potential caveats in mind, the findings from this study indicate the potential utility for
289 prospective proteogenomic variant identification, initiating at disease diagnosis, for the targeted
290 treatment of pediatric relapse ALL.

291 **ACKNOWLEDGEMENTS**

292 This work was supported by the Michael Cuccione Foundation (MCF) and the BC Children's
293 Hospital Foundation through the Better Responses through Avatars and Evidence (BRAVE)
294 Initiative. Salary support was provided by the MCF (CJL, GSDR, CAM, PFL), the Canada
295 Research Chairs Program (PFL), the Michael Smith Foundation for Health Research Scholar
296 Program (PFL) and the University of British Columbia (AL, EKE).


297 Affiliations of authors: Department of Pediatrics, University of British Columbia, Vancouver,
298 BC, Canada (AL, MG, NMA, CJL, GSDR, CAM); Michael Cuccione Childhood Cancer
299 Research Program, BC Children's Hospital, Vancouver, BC, Canada (AL, MG, NMA, CJL,
300 GSDR, PFL, CAM); Department of Pathology, University of British Columbia, Vancouver, BC,
301 Canada (EKE, PFL).

302 We thank Pascal Leclair for contributions made through the BRAVE Initiative and technical
303 assistance. We gratefully acknowledge the participation of the patients and families that made
304 this study possible and the BC Children's Hospital nurses and physicians and Biobank staff for
305 their tremendous efforts in collecting and maintaining specimens. We also acknowledge our
306 consultations with the Modeling node and Proteomics node of the Terry Fox Precision Oncology
307 for Young People Translational Research Program.

308

309


Supplementary Figure 1: Genomic lesions detected in paired ALL specimens from the BCCH cohort



Supplementary Figure 1: Genomic lesions detected in paired ALL specimens from the BCCH cohort

A-K. Line graphs for each patient treated at BCCH represent genomic lesions identified through targeted NGS in samples collected through disease progression. Only abnormal variants are plotted. CNVs are plotted by the number of copies detected and SNVs are plotted by the allelic frequency. Venn diagrams for each patient display variants that are unique to diagnosis (Dx unique), unique to relapse (R unique), or shared between samples in a progression series. An asterisk indicates the lesion is a gene-fusion detected by RNA analysis.

Supplementary Figure 2: Genomic lesions detected in paired ALL specimens from the SJH cohort




Supplementary Figure 2: Genomic lesions detected in paired ALL specimens from the SJH cohort

A. Bar graphs for each patient with B-ALL treated at SJH (n=49) illustrate the fraction of variants that are unique to diagnosis (Dx Unique, dark purple bars), unique to relapse (R unique, light purple bars), or shared (green bars), identified through whole genome sequencing in samples collected through disease progression. Venn diagrams are shown for selected patients to display the distribution of variants in a progression series.

B. Bar graphs for each patient with T-ALL treated at SJH (n=20) illustrate the fraction of variants that are unique to diagnosis (Dx Unique, dark purple bars), unique to relapse (R unique, light purple bars), or shared (green bars), identified through whole genome sequencing in samples collected through disease progression. Venn diagrams are shown for selected patients to display the distribution of variants in a progression series.

Supplementary Figure 3: Dynamics of genomic lesions detected in the SJH and BCCH cohorts



Supplementary Figure 3: Dynamics of genomic lesions detected in the SJH and BCCH cohorts

A. Bar plot for the most frequent variants (top 17) detected in both Dx and paired R samples (shared) plotted as the fraction of samples containing the shared variant in each cohort (n=11 from BCCH, n=69 from SJH). Variants were detected in the BCCH cohort through targeted NGS while variants were detected in the SJH cohort through whole genome sequencing. Thus, variants that cannot be detected in the BCCH samples with the targeting sequencing assay are indicated with ^.


B. Bar plot for the most prevalent genes (top 16) detected in the combined BCCH and SJH cohorts. Variants are categorized as shared (green), Dx unique (dark purple) or R unique (light purple) and plotted as the fraction of occurrences. The total number of times the gene was identified is displayed on the right end of the bar.

C. Bar plot classifying variants (SNV, CNV, Fusion) as shared (green), Dx unique (dark purple) or R unique (light purple) and plotted as the fraction of occurrence in the BCCH cohort.

D. Dot plot for fraction of shared variants versus time to relapse for 59 B-ALL patients (n= 10 from BCCH represented by light blue circle, n= 49 from SJH represented by dark blue circles).

E. Dot plot for fraction of shared variants versus time to relapse for 21 T-ALL patients (n= 1 from BCCH represented by light blue circle, n= 20 from SJH represented by dark blue circles).

Supplementary Figure 4: Description of proteomic data filtering pipeline and quality assessment



Supplementary Figure 4: Description of proteomic data filtering pipeline and quality assessment

A. Total proteins identified in each sample, prior to any filtering. The category of the sample type is listed across the top of each group.


B. Diagram of the filtering workflow to attain the final proteomics dataset utilized for subsequent analyses.

C. Upset plot for ten of the eleven standards (standard nine was removed due to a clear technical issue). Numbers reported are based on proteins quantified by a minimum of two peptides at a precursor q-value threshold of 0.5% FDR.

D. The cv for protein quantity across the ten standards was assessed and plotted by percent coefficient of variation (CV). The darkest purple bar at the bottom represents the number of proteins with a CV of less than 10% and so on, with the lightest bar at the top representing the number of proteins with a cv greater than 50%. This fraction of proteins with cv >50% was removed from the remaining data with the assumption these are unstably quantified between samples.

E. A violin plot demonstrating the median CV of protein quantification across the ten standards (including those >50% CV). Dashed line indicates the median CV (15.7%).

Supplementary Figure 5: Evaluation of individual sample data quality




Supplementary Figure 5: Evaluation of individual sample data quality

A. Bar plot to demonstrate data completeness between replica of each sample. Proteins that were identified in both replica are represented in black, dark grey represents proteins that were only identified in one of the replica, and light grey represents proteins that were entirely missing from the pair.

B. CV between replica is represented as described in panel S5 D; The darkest color bar at the bottom represents the number of proteins with a CV of less than 10% and so on, with the lightest bar at the top representing the number of proteins with a cv greater than 50%.

C. Unsupervised hierarchical clustering was performed to evaluate any bias due to batch effects. Colors represent batches. The standards are represented in grey, as these were a mix of samples from different batches.


Supplementary Figure 6: Significant cancer associated proteins (CAPs)



Supplementary Figure 6: Significant cancer associated proteins (CAPs)

- A.** 141 proteins were tested using LIMMA ($\log_2FC > 1$, p-value adjusted $FDR < 0.05$); Initial Diagnosis (Dx) samples vs. Non-cancer BM samples on the left and Relapse (R) vs Non-cancer BM samples on the right. Proteins that are significantly over expressed in both Dx and R are colored in green and those that are unique to either Dx or R are colored in purple.
- B.** From the list of 269 pediatric cancer driving proteins (black circle), 141 proteins were detected in our data (gray circle) and 45 proteins were deemed significant (red circle).
- C.** Sixteen of the overexpressed proteins were shared between Dx and R (bottom)
- D.** Of the 45 proteins that were overexpressed at Dx, the protein expression for each protein at each timepoint was plotted as timepoint 1 (T1) vs timepoint 2 (T2) (calculated as the $\log_2(\text{protein expression}/\text{the average protein expression in the non-cancer bone marrow (BM) samples})$). A Pearson's r correlation was calculated for the entire dataset.
- E.** Of the 45 proteins that were under-expressed at Dx, the protein expression for each protein at each timepoint was plotted as timepoint 1 (T1) vs timepoint 2 (T2) (calculated as the $\log_2(\text{protein expression}/\text{the average protein expression in the non-cancer bone marrow (BM) samples})$). A Pearson's r correlation was calculated for the entire dataset.

Supplementary Figure 7: Statistical analysis of paired samples



Supplementary Figure 7: Statistical analysis of paired samples

A. Summary of tests for differential expression and equivalence between different groups and pairings. Proteins that are statistically equivalent are represented in green (Two-one-sided t-test (TOST) for equivalence, boundaries between $\log_2FC < -1$ and $\log_2FC > 1$), proteins that are statistically different are represented in purple (student's ttest $p\text{-value} < 0.05$, $\log_2FC > 1$). The bar represents the mean equivalence or difference of all protein expression for each pairing within the group.

B. Similar representation for each individual patient pairing of the group "Same patient-diff timepoints" group. The numbers on the right of each bar indicate how many statistically measurable proteins were in each pairing.

310

311 **MATERIALS AND METHODS**

312

313 **Patient samples & non-cancer controls.** Patient specimens were collected by Biobank staff at
314 BC Children's Hospital. Samples were taken with informed consent during routine clinical care.
315 Sample collection and experiments were performed as approved by the University of British
316 Columbia Children & Women's Research Ethics, and conformed with standards defined in the
317 WMA Department of Helsinki and the Department of Health and Human Services Belmont
318 Report.

319

320 Mononuclear cells containing leukemic blasts were isolated by Ficoll-Paque PLUS density
321 centrifugation, viably frozen and preserved. Aliquots of patient samples, and patient clinical
322 information were de-identified prior to release for this study. Leukemia samples were
323 immunophenotyped at the clinical hematopathology laboratory using established ALL subtype-
324 specific 10-colour flow cytometry panels according to clinical standard operating procedures.
325 Patient bone marrow morphology was assessed by hematopathologists and cytogenetics studies
326 were performed by clinical cytogeneticists. Upon receipt of the specimens, patient mononuclear
327 cells were thawed at 37°C for 1-2 minutes, washed 1x in warm RPMI-1640 medium containing
328 10% fetal bovine serum (FBS, Invitrogen, Waltham, Massachusetts, USA) and washed 2x with
329 PBS and stored as $5 \times 10^5 - 1 \times 10^6$ cells per cell pellet.

330

331 Bone marrow stem cells (BMSC) from five non-cancer individuals were initially collected
332 following routine procedures for bone marrow stem cell transplantation, and remaining material
333 was stored viably with the BCCH Biobank. In addition, we obtained bone marrow mononuclear
334 cells from one healthy individual (non-cancer BM). Finally, for analysis of mature B-cells,
335 PBMCs from five patients that did not have any hematological malignancies that were in a
336 similar age range were combined.

337

338 **DNA/RNA extraction and sequencing.** DNA and RNA extraction were performed using an
339 Allprep (Qiagen) workflow. Library preparation and targeted sequencing was performed using
340 the Oncomine Childhood Cancer Research Assay (OCCRA) on an Ion Chef and Ion Torrent S5
341 platforms (Thermo Fisher Scientific) following the manufacturer's protocols. OCCRA comprises

342 2,031 unique DNA-based amplicons to detect SNVs, and CNVs, and 1,701 RNA-based
343 amplicons to detect unique fusion or structural variants (9). The average read depth for the
344 OCCRA panel was $5 \times 10^6 - 7 \times 10^6$ per sample for DNA and $1 \times 10^6 - 2 \times 10^6$ for RNA.
345 SNVs were retrieved with Ion Reporter software (version 5.2). Copy number measurements were
346 retrieved with Ion Reporter software (version 5.2) for genes with >5 probes, including those that
347 were validated for copy number gains as described elsewhere (9).

348
349 **St. Jude's Hospital (SJH) data curation.** Data was downloaded from
350 www.stjude.com/research/site/data/relapsed-all in December 2018. For our analysis, we included
351 patients with Dx-R1 progression. To determine gene mutations as Dx unique, Shared, of Relapse
352 unique, we included genes listed as “rise” as a shared mutation and genes listed as “fall” as Dx
353 unique (Supplementary Table S3).

354
355 **Cytotoxicity analysis of variant-predicted drug response in paired Dx-R ALL samples.**
356 hTERT-immortalized mesenchymal stromal cells (MSCs) were provided by D. Campana (St.
357 Jude's Hospital). hTERT-MSCs were seeded at 5,000 cells per well in 200 μ L of RPMI-1640
358 medium containing 10% fetal bovine serum (FBS, Invitrogen) and 1 μ M hydrocortisone (Sigma)
359 in a 96-well plate (Corning, Corning, New York, USA), 24 hours prior to seeding with primary
360 B-ALL or non-cancer bone marrow stem cells. Primary samples were thawed at 37°C for 1-2
361 minutes, washed 1x in warm RPMI-1640 medium containing 10% FBS and washed 2x with
362 PBS, and stained with DAPI CFSE stain (Invitrogen) used to distinguish the ALL cells from the
363 hTERT-MSC cells. The media was removed before adding 5×10^4 B-ALL cells in 100 μ L of
364 AIM-V medium (Thermo-Fisher).

365
366 Drug dilutions were prepared at 2x the final concentration (1nM, 10nM, 100nM, 1 μ M, 20 μ M,
367 and 30 μ M) and 100 μ L of each drug dilution was added to 100 μ L of primary cells in each well.
368 Cells were incubated with the drugs for 72 hours at 37°C in a 5% (v/v) CO₂ incubator. Drugs
369 used in the study: Palbociclib, Trametinib, Ruxolitinib, and Vismodegib (Selleck Chemicals
370 LLC, Houston, TX, USA). For PARP1/2 inhibitors, the drugs were prepared for final
371 concentrations of 1nM to 100 μ M in 10-fold increments PJ34 (SelleckChem), 0.1nM to 10 μ M in
372 10-fold increments for Olaparib (SelleckChem).

373

374 After 72 hours, GFP viability dye was added and incubated at room temperature for 1 hour. The
375 plate was analyzed by a high content image analysis system (ImageXpress Micro XL). Images
376 were taken using a 40X 0.75 NA dry objective with the MetaXpress 5.0.2.0 software (Molecular
377 Devices Inc) on the ImageXpress Micro XL epifluorescence microscope (Molecular Devices
378 Inc). DAPI and GFP (green fluorescent protein) emissions were acquired simultaneously with a
379 505DCXR beam splitter (Dual-View; Optical Insights, LLC) with the optical filters for DAPI
380 excitation or GFP emission, respectively. For the analysis of the proportion of living cells,
381 images were taken once per site using 50-ms exposures, 2x2 binned resolution, with 100% of full
382 lamp intensity for each channel, and 25 optical sections spaced 500 μm apart. Post-acquisition
383 processing of images was performed using MetaXpress offline.

384

385 Viability was calculated by taking the mean of (DAPI and GFP double-positive (DP) cells)/
386 (DAPI single-positive cells) for each drug-treated well. To account for relative viability of the
387 primary cells in the assay, the drug-treated viability was normalized to the calculated viability for
388 the vehicle-treated (DMSO) cells. For PARP1/2 inhibitors, normalized viability was assessed by
389 the summation of DP cells across four sites in drug-treated wells / summation of DP cells across
390 4 sites in DMSO-treated wells. IC50 concentrations were calculated in GraphPad PRISM version
391 9 (GraphPad Software, San Diego, CA, USA) with the method “log inhibitor concentration vs
392 normalized response”.

393

394 **Protein extraction and LC-MS/MS acquisition.** Unless otherwise stated, reagents were
395 purchased from Sigma Aldrich (St. Louis, Missouri, United States). Pellets of 5×10^5 – 1×10^6
396 cells were lysed in 50 μl buffer containing 1% SDS (Fisher BioReagents, Pittsburgh,
397 Pennsylvania, United States), 1X Pierce protease inhibitor (Thermo Fisher Scientific) in 50 mM
398 HEPES (pH 8.0), followed by 5 minute incubation at 95 °C and 5 minutes on ice. The sample
399 was incubated with benzonase (EMD Millipore/Novagen, Massachusetts, USA) at 37 °C for 30
400 minutes to shear chromatin. Following benzonase treatment, each sample was reduced with
401 10mM Dithiothreitol (DTT) dissolved in 50mM HEPES pH 8.0 (37°C, 30 minutes) and alkylated
402 with 40 mM Chloroacetamide (CAA) dissolved in 50mM HEPES pH 8.0 (30 minutes in the
403 dark) and quenched in 40 mM DTT for 5 minutes at room temperature.

404
405 Lysates were cleaned using single-pot solid-phase-enhanced (SP3) bead technique (33) using
406 hydrophilic and hydrophobic Sera-Mag Speed Beads (GE Life Sciences, Issaquah, Washington,
407 United States). Proteins were bound to paramagnetic beads with 100% ethanol (80% v/v),
408 incubated for 18 minutes at room temperature, and washed twice with 90% ethanol using
409 magnetic isolation. Beads were then resuspended in 30 μ l 200 mM HEPES, pH 8.0, and
410 incubated with sequencing-grade trypsin (Promega Madison, Wisconsin, United States) at 1:50
411 protein ratio for sixteen hours at 37 °C, and afterwards acidified to pH 3-4 with formic acid.
412 Peptide digests were de-salted on Nest Group Inc. C18 spin columns with 0.1% trifluoroacetic
413 acid (TFA), eluted with 60% acetonitrile in 0.1% FA and dried in a vacuum concentrator. Dried
414 samples were resuspended in 0.1% formic acid (FA).

415
416 **Library Preparation- Gas Phase Fractionation.** Online gas-phase fractionation was
417 performed. 1-2 μ g de-salted peptides from select samples were combined into a single pool and
418 analyzed in ten fractions, 1 μ g per fraction. The first eight fractions (340 m/z to 760 m/z) were
419 analyzed over a 60 m/z window (ie 340 m/z – 400 m/z is fraction 1) each with a loop count of 30
420 and window size of 2 m/z. The final two fractions (820 m/z-1180 m/z) were analyzed over 180
421 m/z window each, with a loop count of 30 and 6 m/z window.

422
423 Peptides were separated on a PharmaFluidics 50cm uPACTM (ESI Source Solutions, Woburn,
424 MA, United States), maintained at 50 °C on an Easy-nLC 1200 connected to a Q Exactive HF
425 mass spectrometer (Thermo Fisher Scientific). The peptides were separated over a 3 hour
426 gradient consisting of Buffer A (0.1% FA in 2% acetonitrile) and 2% to 80% Buffer B (0.1% FA
427 in 95% acetonitrile) at 300 nL/min. MS acquisition consisted of a MS1 scan ranges specified
428 above for each fraction (AGC target of 3e6 or 60 ms injection time), and resolution of 120,000.
429 DIA segment spectra were acquired with a AGC target 3e6, resolution 30,000, auto ms injection
430 time, and stepped collision energy of 25.5, 27, 30. The library was also supplemented with DIA
431 data from each individual sample.

432
433 **Patient Sample MS acquisition.** 1 μ g of peptides was injected for analysis for each sample.
434 Samples were randomized and we obtained duplicate injections. We created a representative

435 pool of 15 ALL primary and cell line samples to be injected approximately every 10 samples for
436 quality control, referred to as “standard”. The DIA method consisted of a MS1 scan from 300 to
437 1650 m/z (AGC target of 3e6 or 60 ms injection time), and resolution of 120,000. DIA segment
438 spectra were acquired with a twenty-four-variable window format, (AGC target 3e6, resolution
439 30,000, auto for injection time), and stepped collision energy of 25.5, 27, 30. We added indexed
440 retention time (iRT) peptides (Biognosys, Schlieren, Switzerland) to each sample for retention
441 time normalization and quality control.

442
443 **Proteomics Data Analysis.** For a summary of data quality and filtering, refer to Supplementary
444 Fig. S4, S5. Briefly, the raw DIA files were analyzed with Spectronaut Pulsar X (Biognosys,
445 Schlieren, Switzerland) using a human FASTA file from UniProt (reviewed 20200309). This
446 FASTA file includes common contaminants. Additionally, a FASTA file for iRT peptides,
447 provided by Biognosys, was included in the search. Search was performed using the factory
448 settings including specificity for Trypsin, Carbamidomethyl (C) as a fixed modification, and
449 Acetyl (protein N-term) and Oxidation (M) as variable modifications. Precursor, and protein
450 identifications false discovery rate (FDR) threshold was set to 1%, while the threshold for
451 peptide was 0.5%. A minimum of 2 peptides were required for quantitation. Protein intensities
452 were normalized in Spectronaut using the “global” setting, which normalizes by median protein
453 intensity per sample. Duplicate injections were averaged (mean). Proteins that were quantified
454 with >50% CV in the 10 standards were removed from all samples as they are presumed to be
455 un-reliably quantified. Furthermore, proteins identified in <10% of the samples were removed.
456 Finally, missing values were imputed using a “down-shifted normal” imputation strategy.
457 Briefly, a normal distribution was created out of the overall sample distribution, then shifted to
458 lower values using magnitude of 3.5.

459
460 To summarize, we identified a total of 8153 unique proteins with an average of 6600 proteins per
461 sample using a data independent acquisition approach (DIA) with a spectral library of 8183
462 proteins derived from gas-phase fractionated sample pool (Supplementary Fig. S4A). After
463 quality assessment and data filtering (Supplementary Fig. S4B), we quantified an average of
464 5100 proteins per sample with at least 2 peptides at less than 0.05% FDR.

465

466 **Identification of cancer-associated proteins.** Proteins were selected from two large-scale
467 pediatric cancer studies that identified commonly mutated genes, genes of prognostic
468 importance, and potential cancer drivers (9,10) (Supplementary Table S6). Additionally, targets
469 were included from the OCCRA panel, which is similar to the Oncomine panels used in NCI-
470 COG Pediatric MATCH precision medicine trial (21) (Supplementary Table S6).

471
472 For statistical analysis, the “Limma” package for R was used. P-value was adjusted using the
473 Benjamin-Hochberg and the FDR threshold was 5%. Circos plots were created in R using the
474 package “Circularize”; data was first filtered for proteins that were overexpressed relative to the
475 non-cancer controls. Pearson correlation coefficient was calculated for each pairing based on
476 proteins that were overexpressed in Dx.

477
478 **Fluorescence-activated cell sorting to isolate mature B-cells.** To investigate comparison to B-
479 cells, we included data from naïve and memory B-cells isolated by flow cytometry from age-
480 matched PBMCs. To decrease processing and patient-specific variability and increase sorting
481 efficiency, we combined PBMCs from five patients that did not have any hematological
482 malignancies and were in a similar age range (see Supplementary Table S1). Briefly, we thawed
483 1 vial (approximately 5×10^6 – 10×10^6 cells per vial) and washed once with sterile FACS
484 buffer (PBS (Thermo Fisher Scientific) + 2% FBS (Thermo Fisher Scientific)). We used
485 25×10^6 live cells for staining. Cells were pelleted and resuspended in approximately 100 μ l of
486 FACS buffer. We utilized a previously established 8-color flow panel designed to identify
487 CD45+ lymphocytes and then optimally separate T-cells and B-cells and their respective
488 subpopulations; for this experiment we aimed to isolate two different mature B-cell populations,
489 naïve B-cells (CD45+CD3-CD19+CD10-CD20+CD27-). and memory B-cells (CD45+CD3-
490 CD19+CD10-CD20+CD27+). The panel consists of CD45-AF488(HI30), CD3-
491 BV510(UCHT1), CD19-APCFire(HIB19), CD4-AlexaFluor700(SK3), CD8-PECy7(RPA-T8),
492 CD10-BV421(HI10a), CD20-APC(2H7), CD27-PE(O323) (BioLegend). We added BV staining
493 cocktail for optimal performance of the BV dye and human FC blocker to reduce unspecific
494 binding. Staining was performed for 20 minutes at 4 °C in the dark. After staining, the cells were
495 washed with FACS buffer, centrifuged at 1500 rpm and resuspended in 1 mL of FACS buffer.

496 Just prior to sorting, we added 7AAD for viability. Sorting was done at the Center for Molecular
497 Medicine and Therapeutics (CMMT) flow sorting core at BCCHR on an Astrios FACS sorter.

498
499 **Statistical Analysis.** To look at protein stability, we established a hybrid method that compares
500 robustly quantified proteins using equivalence and differential expression testing. We normalized
501 the quantitative protein data using median centring and standard samples 1,2,3, and 9 were
502 removed. To create a robust comparison between statistically different and equivalent proteins
503 for a given pair of samples, we employed coefficient of variation (CV) based filtration to filter
504 out proteins with unstable quantification. Proteins with >20% CV between the technical replica
505 for each sample were removed. Only proteins that passed this threshold in each-pairwise
506 comparison remained, therefore there were no missing values or imputed data. The statistical
507 tests were done on each pair of sample comparisons with their two technical replicates. The
508 differential expression testing was done using a `ttest_ind` function from the stats package.
509 Proteins resulting with $p\text{-value} < 0.05$ and $\log\text{FC} > 1$ were designated as statistically different.
510 The equivalence testing was done using the `TOST two_raw` function from the TOSTER package
511 setting $\log\text{FC} < -1$ and $\log\text{FC} > 1$ as boundaries for equivalence.

512
513 To obtain a list of equivalent proteins for gene ontology enrichment, we first ensured the protein
514 was equivalent in at least two of the seven Dx-R pairings. We next removed the proteins
515 attributed to “housekeeping” functions by creating a cancer vs. non-cancer pairings equivalent
516 list, which also required the protein was detected in at least two pairings. Housekeeping proteins
517 were then removed from our paired Dx-R equivalence list. To obtain the “difference” list, we
518 similarly required “difference” in protein expression in at least two of the seven Dx-R (or R-R)
519 pairings. To determine if the protein was Dx or R enriched, we first summed the FC across the
520 pairings and if the total FC was below -1 it was considered R enriched, above +1 was considered
521 Dx enriched and in-between was counted for both Dx and R, leading to two lists for analysis
522 (Dx+ both and R+both).

523
524 For gene ontology analysis we used `g:Profiler` (BIIT! Research Group, `g:Profiler` version
525 `e104_eg51_p15_3922dba`, database updated on 07/05/2021) with an FDR threshold of 5%. To
526 attain better resolution of the pathway visualization, we followed a similar strategy previously

527 described (34); we limited the terms to GO: Biological Process (BP) and limited the number of
528 intersections to 1000. For visualization of the enriched terms, we employed Cytoscape (35)
529 (version 3.8.2) and utilized the “EnrichmentMap” and “AutoAnnotate” packages. For TF
530 enrichment, we created a list of equivalent proteins as previously described. However, these
531 proteins had to be identified in at least three of the paired samples, and at least three of the cancer
532 vs. non-cancer pairings. The enrichment was obtained from gProfiler, as described above. The
533 background list for all GO analyses was a list of all proteins quantified in the data set.

534

535 **Data Availability.** MS data have been deposited to the Proteome Consortium
536 (<http://www.proteomexchange.org>) via the MassIVE (<https://massive.ucsd.edu/>) partner
537 repository data set MSV00008897.

538

539 **FIGURE LEGENDS**

540

541 **Figure 1: NGS reveals stability of affected genes through ALL disease progression**

- 542 **A.** Mutated gene products identified through targeted DNA/RNA-fusion sequencing of paired
543 diagnosis (Dx) and relapse (R) samples. Mutations detected in both Dx and R samples are
544 represented by green boxes, mutations unique to Dx are dark purple, and R unique are light
545 purple. CNVs are full boxes and SNVs are outlined boxes. The pie diagrams at the top
546 summarize the number of mutations for each category for each patient. An asterisk indicates
547 multi timepoint patients; BALL01 R2-R3-R4-R5-R5P, BALL02 Dx-R1-R2.
- 548 **B.** Circos plot for all mutations identified in the BCCH cohort demonstrating mutations that
549 were Dx unique, R unique, or shared between Dx and R samples. Genes in blue text indicate
550 genes with detected lesions in both cohorts.
- 551 **C.** Circos plot for all mutations identified in the SJH cohort demonstrating mutations that were
552 Dx unique, R unique, or shared between Dx and R samples. Genes in blue text indicate genes
553 with detected lesions in both cohorts.
- 554 **D.** Fraction of variants identified as D unique, R1 unique, or shared within paired samples
555 sourced from 80 ALL patients (n= 11 from BCCH represented by squares, n= 69 from SJH
556 represented by circles). The black bar represents the median of the population.
- 557 **E.** Dot plot for fraction of shared variants versus time to relapse for 80 ALL patients (n= 11
558 from BCCH represented by squares, n= 69 from SJH represented by circles).
- 559 **F.** Dot plot for fraction of shared variants separated by disease subtype for 80 ALL patients (n=
560 11 from BCCH represented by squares, n= 69 from SJH represented by circles). The black
561 bar represents the median of the population.

562

563 **Figure 2: Matched patient-derived leukemic cells respond similarly to variant-selected**
564 **agents**

- 565 **A.** Predicted sensitivity to targeted agents in paired Dx-R samples (or Dx-R2, R2-R3 indicated
566 by an asterisk) taken from 80 ALL patients treated at BCCH (n=11, light blue) or SJH (n=69,
567 dark blue). B-ALL (light brown) and T-ALL (dark brown) samples are indicated. Shared
568 variants (green), Dx unique variants (dark purple), or R unique variants (light purple) are

569 indicated. Agent-variant pairs were assigned following the strategy outlined in the Pediatric
570 Match Trial (9).

571 **B.** Measured IC₅₀ values for viably frozen ALL samples from patients treated at BCCH (n= 6
572 patients) and representative cell lines. ALL samples were co-cultured with hTERT-MSCs
573 and separately treated with four inhibitors, MEKi, CDK4/6i, JAK/STATi, and SMOi. IC₅₀
574 [μM] are colored by most sensitive in yellow to least sensitive in blue. Measurements
575 represent the mean of n=2 replica wells from a single experiment.

576 **C.** Dot plots for IC₅₀ [μM] values measured for primary samples or cell lines for each drug.
577 Samples are separated based on the presence (pink) or absence (black) of a genomic variant
578 predicted to augment drug sensitivity.

579 **D.** Correlation of IC₅₀ [M] values measured for paired Dx and R paired samples. Individual
580 drugs are indicated by unique identifiers. r= Pearson correlation coefficient.

581

582 **Figure 3: Proteome investigation of matched specimens reveals stable levels of cancer-**
583 **associated proteins and processes**

584 **A.** From the list of 269 pediatric cancer associated proteins (CAPs), 141 proteins were detected
585 in our data and 45 proteins were deemed significant (LIMMA analysis of Initial Diagnosis
586 (Dx) samples vs. non-cancer bone marrow (BM) samples and Relapse (R) vs non-cancer BM
587 samples (log₂FC>1, p-value adjusted BH-FDR<0.05). Circos plot summarizes significantly
588 overexpressed cancer associated proteins (CAPs).

589 **B.** Of the 45 proteins that were overexpressed, the protein expression for each protein that was
590 overexpressed at Dx, was plotted as timepoint 1 (T1) vs timepoint 2 (T2), where T1 is the
591 earliest timepoint available for the specimen (calculated as the log₂(protein expression/the
592 average protein expression in the non-cancer BM)). Pearson's r correlation was calculated for
593 all sample pairs. In cases that we had multiple time-points (BALL01 and BALL02) the
594 correlation was calculated for consecutive pairings and are represented by the different
595 colored dots.

596 **C.** Summary of tests for equivalence (Two-one-sided t-test (TOST) for equivalence, boundaries
597 between log₂FC<-1 and log₂FC>1) of protein abundance between different groups and
598 pairings. Only statistically measurable proteins are represented. Each dot represents the mean

- 599 equivalence or difference of all protein abundance for a pairing. Significance is assigned by
600 mann-whitney wilcoxon test, *** indicates $p\text{-value} \leq 0.0001$.
- 601 **D.** Pathway enrichment analysis of the stable population of proteins represented in green and
602 relapse enriched population of proteins represented in purple. The color of the circles
603 indicates the enrichment FDR and size represents the number of identifications for the term.
- 604 **E.** Abundance of transcription factors of interest for each sample separated by timepoint (T1 or
605 T2, black) compared to protein expression in mature B-cells (n=2 samples) isolated from
606 peripheral blood mononuclear cells (grey).
- 607 **F.** Dot plots represent the $\log_2\text{FC}$ of timepoint 1(T1)/timepoint 2(T2) for each of the proteins
608 for each sample. The shaded green area indicates the stable range of -1 to 1FC. *For patients
609 with multiple timepoints (BALL01 and BALL02) only the $\log_2\text{ratio}$ of the earliest
610 timepoint/the latest timepoint is represented for simplicity.
- 611 **G.** Enriched transcription factor (TF) motifs by FDR-adjusted \log_{10} p-value. Light blue text
612 indicates TFs that are regulated by CDK4/6 and MEK pathway. Simplified diagrams of these
613 pathways are demonstrated below

614

615 **Figure 4: Whole proteome discovery-driven analysis identifies pan-ALL protein targets**

- 616 **A.** Correlation of \log_2 fold-change (FC)/non-cancer vs protein expression (\log_{10} intensity) for
617 all proteins in all samples (filtered for proteins identified in at least ten of seventeen
618 samples). Dashed lines represent cut-offs for top five percent of the population for each
619 parameter. Proteins that meet both cut-offs are colored in orange and PARP expression is
620 represented by blue triangles.
- 621 **B.** Representative figure (BALL01) showing all proteins that are $>\log_2\text{FC}$ of 1.7. Only the
622 proteins that have \log_{10} intensity >6.0 (top 5%) are colored in orange.
- 623 **C.** Summary of all proteins of interest (proteins that pass all cut-offs) plotted by number of
624 samples the protein meets the indicated parameters.
- 625 **D.** Measured IC_{50} values for Olaparib or PJ34 measured against ALL or non-cancer samples
626 from patients treated at BCCH (n= 5 non-cancer, 8 diagnostic samples, 10 relapse samples).
627 Samples were co-cultured with hTERT-MSCs and separately treated with the two PARP1/2
628 inhibitors. IC_{50} [μM] are colored by most sensitive in yellow to least sensitive in blue.

629 Measurements represent the mean of n=2 replica wells from a single experiment. Bolded
630 Patient IDs indicate patient samples analyzed in the pan-ALL target proteomic analysis.
631 **E.** Dot plots for IC50 [μ M] values for Olaparib or PJ34 measured against non-cancer specimens
632 (black square), primary diagnostic samples (light brown circle) or primary relapse samples
633 (black circle). Measurements represent the mean of n=2 replica wells from a single
634 experiment. Significance (*, **) is assigned by unpaired student's t-test p-value <0.01 and p-
635 value <0.001 respectively.

636 **SUPPLEMENTARY FIGURE LEGENDS**

637 638 **Supplementary Figure S1: Genomic lesions detected in paired ALL specimens from the** 639 **BCCH cohort**

640 **A-K.** Line graphs for each patient treated at BCCH represent genomic lesions identified through
641 targeted NGS in samples collected through disease progression. Only abnormal variants are
642 plotted. CNVs are plotted by the number of copies detected and SNVs are plotted by the allelic
643 frequency. Venn diagrams for each patient display variants that are unique to diagnosis (Dx
644 unique), unique to relapse (R unique), or shared between samples in a progression series. An
645 asterisk indicates the lesion is a gene-fusion detected by RNA analysis.

646 647 **Supplementary Figure S2: Genomic lesions detected in paired ALL specimens from the** 648 **SJH cohort**

649 **A.** Bar graphs for each patient with B-ALL treated at SJH (n=49) illustrate the fraction of
650 variants that are unique to diagnosis (Dx Unique, dark purple bars), unique to relapse (R
651 unique, light purple bars), or shared (green bars), identified through whole genome
652 sequencing in samples collected through disease progression. Venn diagrams are shown for
653 selected patients to display the distribution of variants in a progression series.

654 **B.** Bar graphs for each patient with T-ALL treated at SJH (n=20) illustrate the fraction of
655 variants that are unique to diagnosis (Dx Unique, dark purple bars), unique to relapse (R
656 unique, light purple bars), or shared (green bars), identified through whole genome
657 sequencing in samples collected through disease progression. Venn diagrams are shown for
658 selected patients to display the distribution of variants in a progression series.

659 **Supplementary Figure S3: Dynamics of genomic lesions detected in the SJH and BCCH**
660 **cohorts**

- 661 **A.** Bar plot for the most frequent variants (top 17) detected in both Dx and paired R samples
662 (shared) plotted as the fraction of samples containing the shared variant in each cohort (n=11
663 from BCCH, n=69 from SJH). Variants were detected in the BCCH cohort through targeted
664 NGS while variants were detected in the SJH cohort through whole genome sequencing.
665 Thus, variants that cannot be detected in the BCCH samples with the targeting sequencing
666 assay are indicated with ^.
- 667 **B.** Bar plot for the most prevalent genes (top 16) detected in the combined BCCH and SJH
668 cohorts. Variants are categorized as shared (green), Dx unique (dark purple) or R unique
669 (light purple) and plotted as the fraction of occurrences. The total number of times the gene
670 was identified is displayed on the right end of the bar.
- 671 **C.** Bar plot classifying variants (SNV, CNV, Fusion) as shared (green), Dx unique (dark purple)
672 or R unique (light purple) and plotted as the fraction of occurrence in the BCCH cohort.
- 673 **D.** Dot plot for fraction of shared variants versus time to relapse for 59 B-ALL patients (n= 10
674 from BCCH represented by light blue circle, n= 49 from SJH represented by dark blue
675 circles).
- 676 **E.** Dot plot for fraction of shared variants versus time to relapse for 21 T-ALL patients (n= 1
677 from BCCH represented by light blue circle, n= 20 from SJH represented by dark blue
678 circles).
- 679

680 **Supplementary Figure S4: Description of proteomic data filtering pipeline and quality**
681 **assessment**

- 682 **A.** Total proteins identified in each sample, prior to any filtering. The category of the sample
683 type is listed across the top of each group.
- 684 **B.** Diagram of the filtering workflow to attain the final proteomics dataset utilized for
685 subsequent analyses.
- 686 **C.** Upset plot for ten of the eleven standards (standard nine was removed due to a clear technical
687 issue). Numbers reported are based on proteins quantified by a minimum of two peptides at a
688 precursor q-value threshold of 0.5% FDR.

- 689 **D.** The cv for protein quantity across the ten standards was assessed and plotted by percent
690 coefficient of variation (CV). The darkest purple bar at the bottom represents the number of
691 proteins with a CV of less than 10% and so on, with the lightest bar at the top representing
692 the number of proteins with a cv greater than 50%. This fraction of proteins with cv >50%
693 was removed from the remaining data with the assumption these are unstably quantified
694 between samples.
- 695 **E.** A violon plot demonstrating the median CV of protein quantification across the ten standards
696 (including those >50% CV). Dashed line indicates the median CV (15.7%).
697

698 **Supplementary Figure S5: Evaluation of individual sample data quality**

- 699 **A.** Bar plot to demonstrate data completeness between replica of each sample. Proteins that were
700 identified in both replica are represented in black, dark grey represents proteins that were
701 only identified in one of the replica, and light grey represents proteins that were entirely
702 missing from the pair.
- 703 **B.** CV between replica is represented as described in panel S5 D; The darkest color bar at the
704 bottom represents the number of proteins with a CV of less than 10% and so on, with the
705 lightest bar at the top representing the number of proteins with a cv greater than 50%.
- 706 **C.** Unsupervised hierarchical clustering was performed to evaluate any bias due to batch effects.
707 Colors represent batches. The standards are represented in grey, as these were a mix of
708 samples from different batches.
709

710 **Supplementary Figure S6: Significant cancer associated proteins (CAPs)**

- 711 **A.** 141 proteins were tested using LIMMA ($\log_2FC > 1$, p-value adjusted FDR < 0.05); Initial
712 Diagnosis (Dx) samples vs. Non-cancer BM samples on the left and Relapse (R) vs Non-
713 cancer BM samples on the right. Proteins that are significantly over expressed in both Dx and
714 R are colored in green and those that are unique to either Dx or R are colored in purple.
- 715 **B.** From the list of 269 pediatric cancer driving proteins (black circle), 141 proteins were
716 detected in our data (gray circle) and 45 proteins were deemed significant (red circle).
- 717 **C.** Sixteen of the overexpressed proteins were shared between Dx and R (bottom)
- 718 **D.** Of the 45 proteins that were overexpressed at Dx, the protein expression for each protein at
719 each timepoint was plotted as timepoint 1 (T1) vs timepoint 2 (T2) (calculated as the

720 $\log_2(\text{protein expression}/\text{the average protein expression in the non-cancer bone marrow (BM)}$
721 $\text{samples})$. A Pearson's r correlation was calculated for the entire dataset.

722 **E.** Of the 45 proteins that were under-expressed at Dx, the protein expression for each protein at
723 each timepoint was plotted as timepoint 1 (T1) vs timepoint 2 (T2) (calculated as the
724 $\log_2(\text{protein expression}/\text{the average protein expression in the non-cancer bone marrow (BM)}$
725 $\text{samples})$. A Pearson's r correlation was calculated for the entire dataset.

726 **Supplementary Figure S7: Statistical analysis of paired samples**

727 **A.** Summary of tests for differential expression and equivalence between different groups and
728 pairings. Proteins that are statistically equivalent are represented in green (Two-one-sided t-
729 test (TOST) for equivalence, boundaries between $\log_2\text{FC} < -1$ and $\log_2\text{FC} > 1$), proteins that
730 are statistically different are represented in purple (student's ttest $p\text{-value} < 0.05$, $\log_2\text{FC} > 1$).
731 The bar represents the mean equivalence or difference of all protein expression for each
732 pairing within the group.

733 **B.** Similar representation for each individual patient pairing of the group "Same patient-diff
734 timepoints" group. The numbers on the right of each bar indicate how many statistically
735 measurable proteins were in each pairing.

736

737 **Bibliography**

- 738 1. Ellison LF, De P, Mery LS, Grundy PE, Canadian Cancer Society's Steering
739 Committee for Canadian Cancer Statistics. Canadian cancer statistics at a glance:
740 cancer in children. *Can Med Assoc J*. 2009 Feb 17;180(4):422–424.
- 741 2. Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers:
742 Implications for diagnosis and treatment. *Science*. 2019 Mar 15;363(6432):1170–1175.
- 743 3. Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and
744 fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic
745 leukaemia. *Nat Commun*. 2015 Mar 19;6:6604.
- 746 4. Oshima K, Khiabani H, da Silva-Almeida AC, Tzoneva G, Abate F, Ambesi-
747 Impiombato A, et al. Mutational landscape, clonal evolution patterns, and role of
748 RAS mutations in relapsed acute lymphoblastic leukemia. *Proc Natl Acad Sci USA*.
749 2016 Oct 4;113(40):11306–11311.
- 750 5. Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M,
751 Madubata CJ, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute
752 lymphoblastic leukaemia. *Nature*. 2018 Jan 25;553(7689):511–514.
- 753 6. Schroeder MP, Bastian L, Eckert C, Gökbuget N, James AR, Tanchez JO, et al.
754 Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia
755 identifies subtype-specific cytokine and metabolic signatures. *Sci Rep*. 2019 Mar
756 12;9(1):4188.
- 757 7. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA,
758 et al. The landscape of genomic alterations across childhood cancers. *Nature*. 2018
759 Mar 15;555(7696):321–327.
- 760 8. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer
761 genome and transcriptome analyses of 1,699 paediatric leukaemias and solid
762 tumours. *Nature*. 2018 Mar 15;555(7696):371–376.
- 763 9. Lorentzian A, Biegel JA, Ostrow DG, Rolf N, Liu C-C, Rassekh SR, et al. Tumor
764 variant identification that accounts for the unique molecular landscape of pediatric
765 malignancies. *JNCI Cancer Spectr*. 2018 Oct;2(4):pky079.
- 766 10. Waanders E, Dobson SM, Ma X, Payne-Turner D, Song G, Fan Y, et al. Genomic
767 landscape of relapsed acute lymphoblastic leukemia. *Blood*. 2015 Dec 3;126(23):692–
768 692.
- 769 11. Tran TH, Shah AT, Loh ML. Precision Medicine in Pediatric Oncology: Translating
770 Genomic Discoveries into Optimized Therapies. *Clin Cancer Res*. 2017 Sep
771 15;23(18):5329–5338.
- 772 12. Somasundaram R, Prasad MAJ, Ungerback J, Sigvardsson M. Transcription factor
773 networks in B-cell differentiation link development to acute lymphoid leukemia.
774 *Blood*. 2015 Jul 9;126(2):144–152.
- 775 13. Lim JSJ, Tan DSP. Understanding resistance mechanisms and expanding the
776 therapeutic utility of PARP inhibitors. *Cancers (Basel)*. 2017 Aug 22;9(8).
- 777 14. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition:
778 PARP1 and beyond. *Nat Rev Cancer*. 2010 Apr;10(4):293–301.
- 779 15. Langenberg KPS, Looze EJ, Molenaar JJ. The landscape of pediatric precision
780 oncology: program design, actionable alterations, and clinical trial development.
781 *Cancers (Basel)*. 2021 Aug 27;13(17).

- 782 16. Wong M, Mayoh C, Lau LMS, Khuong-Quang D-A, Pinese M, Kumar A, et al. Whole
783 genome, transcriptome and methylome profiling enhances actionable target discovery
784 in high-risk pediatric cancer. *Nat Med.* 2020 Nov;26(11):1742–1753.
- 785 17. van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, et al. The
786 Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for
787 Patients with Very High-Evidence Targets. *Cancer Discov.* 2021 Nov;11(11):2764–
788 2779.
- 789 18. Andersson N, Bakker B, Karlsson J, Valind A, Holmquist Mengelbier L, Spierings
790 DCJ, et al. Extensive Clonal Branching Shapes the Evolutionary History of High-Risk
791 Pediatric Cancers. *Cancer Res.* 2020 Apr 1;80(7):1512–1523.
- 792 19. Karlsson J, Valind A, Holmquist Mengelbier L, Bredin S, Cornmark L, Jansson C, et
793 al. Four evolutionary trajectories underlie genetic intratumoral variation in
794 childhood cancer. *Nat Genet.* 2018 Jul;50(7):944–950.
- 795 20. Sayyab S, Lundmark A, Larsson M, Ringnér M, Nystedt S, Marincevic-Zuniga Y, et
796 al. Mutational patterns and clonal evolution from diagnosis to relapse in pediatric
797 acute lymphoblastic leukemia. *Sci Rep.* 2021 Aug 6;11(1):15988.
- 798 21. Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, et al.
799 Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated
800 childhood acute lymphoblastic leukemia through upregulation of BIM.
801 *Haematologica.* 2019 Sep;104(9):1804–1811.
- 802 22. Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway
803 mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and
804 confer sensitivity to MEK inhibition. *Blood.* 2014 Nov 27;124(23):3420–3430.
- 805 23. Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, et al.
806 Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
807 *Cancer Biol Ther.* 2020;21(3):197–202.
- 808 24. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond
809 cell cycle arrest. *Trends Cell Biol.* 2018 Jul 27;28(11):911–925.
- 810 25. Gong X, Litchfield LM, Webster Y, Chio L-C, Wong SS, Stewart TR, et al. Genomic
811 Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to
812 the CDK4 and CDK6 Inhibitor Abemaciclib. *Cancer Cell.* 2017 Dec 11;32(6):761–
813 776.e6.
- 814 26. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to
815 therapy. *Cancer Discov.* 2016 Apr;6(4):353–367.
- 816 27. Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, et al. Path toward
817 Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in
818 Defining “Actionability” of a Molecular Lesion and Patient Management Support.
819 *Mol Cancer Ther.* 2017 Dec;16(12):2645–2655.
- 820 28. Grover SA, Alcindor T, Berman JN, Chan JA, Denburg AE, Deyell RJ, et al. Abstract
821 636: PROFYLE: The pan-Canadian precision oncology program for children,
822 adolescents and young adults with hard-to-treat cancer. *Clinical Research (Excluding
823 Clinical Trials).* American Association for Cancer Research; 2021. p. 636–636.
- 824 29. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of
825 phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell.* 2007 Dec
826 14;131(6):1190–1203.

- 827 **30. Doll S, Gnad F, Mann M. The Case for Proteomics and Phospho-Proteomics in**
828 **Personalized Cancer Medicine. *Proteomics Clin Appl.* 2019;13(2):e1800113.**
- 829 **31. Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, et**
830 **al. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and**
831 **Immunotherapy Target in Ovarian Cancer. *Cell.* 2018 Sep 20;175(1):159–170.e16.**
- 832 **32. Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al. Ex vivo**
833 **drug response profiling detects recurrent sensitivity patterns in drug-resistant acute**
834 **lymphoblastic leukemia. *Blood.* 2017 Mar 16;129(11):e26–e37.**
- 835 **33. Hughes CS, Moggridge S, Müller T, Sorensen PH, Morin GB, Krijgsveld J. Single-**
836 **pot, solid-phase-enhanced sample preparation for proteomics experiments. *Nat***
837 **Protoc.** 2019 Jan;14(1):68–85.
- 838 **34. Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al.**
839 **Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA,**
840 **Cytoscape and EnrichmentMap. *Nat Protoc.* 2019 Feb;14(2):482–517.**
- 841 **35. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a**
842 **software environment for integrated models of biomolecular interaction networks.**
843 ***Genome Res.* 2003 Nov;13(11):2498–2504.**
844
845